Bristol Myers Squibb just paid up to $2.3B USD for IFM Therapeutics, a preclinical cancer immunotherapy company. $300MM upfront and up to $1.01B for each of IFM's two therapeutics depending on milestones met. Be nice to see what a ph3 cardio company with ph 2/3 renal and multiple other compounds could command. Hopefully management is on top of things.  Not an apples to apples comparison but interesting nonetheless.